Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages
MarketBeat
Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, si
NASDAQ:LYEL